BAYRY
Bayer AG (ADR)

2,753
Loading...
Loading...
News
all
press releases
REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?
Regeneron shares slump as Eylea struggles, but Dupixent gains and a strengthening oncology pipeline offer growth potential.
Zacks·6d ago
News Placeholder
More News
News Placeholder
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer
Big Pharma faces tariff risks, patent cliffs, and regulatory pressure, but innovation and strong pipelines keep Eli Lilly, J&J, Novartis, Pfizer, and Bayer in focus.
Zacks·11d ago
News Placeholder
5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, Novartis, Pfizer and Bayer are worth retaining amid macro pressure and rising innovation.
Zacks·11d ago
News Placeholder
Are Medical Stocks Lagging Bayer (BAYRY) This Year?
Here is how Bayer Aktiengesellschaft (BAYRY) and BioLife Solutions, Inc. (BLFS) have performed compared to their sector so far this year.
Zacks·12d ago
News Placeholder
RHHBY Posts Positive Data on Vabysmo in nAMD at Euretina Congress
Roche posts strong new data for Vabysmo in eye disease, with extended dosing and vision gains driving growth.
Zacks·16d ago
News Placeholder
Should Value Investors Buy Bayer (BAYRY) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks·24d ago
News Placeholder
ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression
AbbVie is acquiring Gilgamesh's lead psychedelic drug bretisilocin for up to $1.2B, aiming to expand its depression treatment pipeline
Zacks·27d ago
News Placeholder
FDA Extends Review Period of REGN's Submission for Eylea HD
The FDA extends action dates for Regeneron's Eylea HD filings following inspection findings at Catalent Indiana. Nonetheless, Eylea HD remains available through vial administration.
Zacks·1mo ago
News Placeholder
Top Analyst Reports for Netflix, Mastercard & Shell
Netflix's ad tier drives over 55% of new sign-ups as its content slate and global strategy fuel a bold revenue growth target for 2030.
Zacks·1mo ago
News Placeholder
Can Eylea HD and Dupixent Profits Revive Regeneron Stock?
REGN banks on Dupixent and Eylea HD gains to offset Eylea's decline while oncology wins strengthen its diversified pipeline.
Zacks·1mo ago

Latest BAYRY News

View

Advertisement. Remove ads.

Advertisement. Remove ads.